Cholesterol sulfate inhibits osteoclast differentiation and survival by regulating the AMPK–Sirt1–NF‐κB pathway
Journal of Cellular Physiology · 2023
DOI: 10.1002/jcp.31064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Physiology, 2023. Verfasst von Jin Ha Park und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science and the Research Center for Cellular Homeostasis, Ewha Womans University, Seoul, Korea. Hauptthemen laut MEDLINE: Bone Resorption, NF-kappa B, Cholesterol Esters. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Cholesterol sulfate (CS) is an activator of retinoic acid‐related orphan receptor α (RORα). CS treatment or RORα overexpression attenuates osteoclastogenesis in a collagen‐induced arthritis mouse model. However, the mechanism by which CS and RORα regulate osteoclast differentiation remains largely unknown. Thus, we aimed to investigate the role of CS and RORα in osteoclastogenesis and their underlying mechanism. CS inhibited osteoclast differentiation, but RORα deficiency did not affect osteoclast differentiation and CS‐mediated inhibition of osteoclastogenesis. CS enhanced adenosine monophosphate‐activated protein kinase (AMPK) phosphorylation and sirtuin1 (Sirt1) activity, leading to nuclear factor‐κB (NF‐κB) inhibition by decreasing acetylation at Lys310 of p65. The NF‐κB inhibition was restored by AMPK inhibitor, but the effects of CS on AMPK and NF‐κB were not altered by RORα deficiency. CS also induced osteoclast apoptosis, which may be due to sustained AMPK activation and consequent NF‐κB inhibition, and the effects of CS were significantly reversed by interleukin‐1β treatment. Collectively, these results indicate that CS inhibits osteoclast differentiation and survival by suppressing NF‐κB via the AMPK–Sirt1 axis in a RORα‐independent manner. Furthermore, CS protects against bone destruction in lipopolysaccharide‐ and ovariectomy‐mediated bone loss mouse models, suggesting that CS is a useful therapeutic candidate for treating inflammation‐induced bone diseases and postmenopausal osteoporosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Science and the Research Center for Cellular Homeostasis, Ewha Womans University, Seoul, Korea.
- College of Pharmacy and Bio-MAX Institute, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.
ORCID-Profile: Mi-Ock Lee, Woojin Jeong
Förderung
- National Research Foundation of Korea
Zitieren
APA
Park, J. H., Lee, J., Lee, G. R., Kwon, M., Lee, H. I., Kim, N., Kim, H. J., Lee, M. O., & Jeong, W. (2023). Cholesterol sulfate inhibits osteoclast differentiation and survival by regulating the AMPK–Sirt1–NF‐κB pathway. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.31064
Vancouver
Park JH, Lee J, Lee GR, Kwon M, Lee HI, Kim N, et al. Cholesterol sulfate inhibits osteoclast differentiation and survival by regulating the AMPK–Sirt1–NF‐κB pathway. Journal of Cellular Physiology. 2023. doi:10.1002/jcp.31064
BibTeX
@article{Park2023,
author = {Park, Jin Ha and Lee, Jiae and Lee, Gong-Rak and Kwon, Minjeong and Lee, Hye In and Kim, Narae and Kim, Hee Jin and Lee, Mi-Ock and Jeong, Woojin},
title = {Cholesterol sulfate inhibits osteoclast differentiation and survival by regulating the AMPK–Sirt1–NF‐κB pathway},
journal = {Journal of Cellular Physiology},
year = {2023},
doi = {10.1002/jcp.31064}
}
EUVIMED